GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

olezarsen   Click here for help

GtoPdb Ligand ID: 13658

Synonyms: AKCEA-APOCIII-LRX | IONIS-APOCIII-LRX | ISIS-678354 | ISIS-APOCIII-LRX | Tryngolza®
Approved drug
olezarsen is an approved drug (FDA (2024))
Compound class: Nucleic acid
Comment: Olezarsen is an antisense GalNAc3-conjugated oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C-III (APOC3) as a mechanism to treat dyslipidemias [2-4,6]. The nucleotide sequence is chemically modified to optimise in vivo stability and hepatic delivery. We have been unable to resolve a full SMILES or HELM notation for the entire ASO.
Classification Click here for help
Compound class Nucleic acid
Compound subclass Antisense oligonucleotide (ASO)
Target apolipoprotein C-III (APOC3) mRNA
Approved drug? Yes. US FDA (2024)
International Nonproprietary Names Click here for help
INN number INN
11801 olezarsen
Synonyms Click here for help
AKCEA-APOCIII-LRX | IONIS-APOCIII-LRX | ISIS-678354 | ISIS-APOCIII-LRX | Tryngolza®
Database Links Click here for help
CAS Registry No. 2097587-83-0 (source: WHO INN record)
DrugBank Ligand DB18728
GtoPdb PubChem SID 507750292
Search PubMed clinical trials olezarsen
Search PubMed titles olezarsen
Search PubMed titles/abstracts olezarsen